JP2014515407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515407A5 JP2014515407A5 JP2014513785A JP2014513785A JP2014515407A5 JP 2014515407 A5 JP2014515407 A5 JP 2014515407A5 JP 2014513785 A JP2014513785 A JP 2014513785A JP 2014513785 A JP2014513785 A JP 2014513785A JP 2014515407 A5 JP2014515407 A5 JP 2014515407A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- bonds
- pharmaceutical formulation
- divalent
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 32
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- -1 triphenylphosphonium cation Chemical group 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 9
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 9
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 9
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 229950010033 ebselen Drugs 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 9
- 235000010384 tocopherol Nutrition 0.000 claims description 9
- 229960001295 tocopherol Drugs 0.000 claims description 9
- 229930003799 tocopherol Natural products 0.000 claims description 9
- 239000011732 tocopherol Substances 0.000 claims description 9
- 229940035936 ubiquinone Drugs 0.000 claims description 9
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 8
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 206010072170 Skin wound Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 15
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims 5
- 125000003277 amino group Chemical group 0.000 claims 5
- 150000001450 anions Chemical class 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 150000001768 cations Chemical class 0.000 claims 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 150000002430 hydrocarbons Chemical group 0.000 claims 5
- 150000002500 ions Chemical class 0.000 claims 5
- 125000000468 ketone group Chemical group 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 5
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 0 CC(C(c1cc(*)c(*)cc11)=O)=CC1=O Chemical compound CC(C(c1cc(*)c(*)cc11)=O)=CC1=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161492940P | 2011-06-03 | 2011-06-03 | |
| US61/492,940 | 2011-06-03 | ||
| PCT/US2012/040711 WO2012167236A1 (en) | 2011-06-03 | 2012-06-04 | Oral formulations of mitochondrially-targeted antioxidants and their preparation and use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017196849A Division JP6461276B2 (ja) | 2011-06-03 | 2017-10-10 | ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515407A JP2014515407A (ja) | 2014-06-30 |
| JP2014515407A5 true JP2014515407A5 (OSRAM) | 2015-07-02 |
| JP6448366B2 JP6448366B2 (ja) | 2019-01-09 |
Family
ID=47259946
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513785A Active JP6448366B2 (ja) | 2011-06-03 | 2012-06-04 | ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用 |
| JP2017196849A Active JP6461276B2 (ja) | 2011-06-03 | 2017-10-10 | ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017196849A Active JP6461276B2 (ja) | 2011-06-03 | 2017-10-10 | ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9192676B2 (OSRAM) |
| EP (1) | EP2714024B1 (OSRAM) |
| JP (2) | JP6448366B2 (OSRAM) |
| CN (1) | CN103764132B (OSRAM) |
| AU (1) | AU2012261854B2 (OSRAM) |
| BR (1) | BR112013030605A2 (OSRAM) |
| CA (1) | CA2837437C (OSRAM) |
| EA (1) | EA031399B1 (OSRAM) |
| ES (1) | ES2704064T3 (OSRAM) |
| WO (1) | WO2012167236A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103764132B (zh) * | 2011-06-03 | 2017-04-12 | 米托特克公司 | 线粒体靶向的抗氧化剂的口服制剂及其制备和用途 |
| US9744180B2 (en) * | 2013-01-22 | 2017-08-29 | Mitotech Sa | Pharmaceutical formulations containing mitochondrially targeted antioxidants |
| EP3030267A2 (en) * | 2013-04-11 | 2016-06-15 | Mitotech SA | Mitochondrially-targeted timoquinones and toluquinones |
| US20160361245A1 (en) * | 2014-02-25 | 2016-12-15 | Mitotech Sa | Cosmetic compositions of mitochondrially targeted antioxidants |
| WO2019139831A1 (en) * | 2018-01-10 | 2019-07-18 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using succinate |
| CN115551476A (zh) * | 2019-12-10 | 2022-12-30 | 米陀科技有限公司 | 用于线粒体靶向抗氧化剂的不同组合物的聚合物基质 |
| EP4125867A1 (en) * | 2020-04-03 | 2023-02-08 | Mitotech S.A. | Use of mitochondria-targeted antioxidants to treat severe inflammatory conditions |
| CN114344274A (zh) * | 2022-01-05 | 2022-04-15 | 盖茨汉普(武汉)植物应用研究有限公司 | 一种Mitoq抗氧化硬胶囊配方及制备工艺 |
| WO2025078880A1 (en) * | 2023-10-11 | 2025-04-17 | Mitotech S.A. | Mitochondria-targeted antioxidants for use in the treatment of cell balloooning-associated diseases, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5538974A (en) | 1994-01-27 | 1996-07-23 | Senju Pharamceutical Co., Ltd. | Ophthalmic composition for lowering intraocular pressure |
| US6331532B1 (en) | 1998-11-25 | 2001-12-18 | University Of Otago | Mitochondrially targeted antioxidants |
| CN1318434C (zh) | 1997-11-25 | 2007-05-30 | 安迪珀蒂恩生物工艺学有限公司 | 线粒体靶向的抗氧剂 |
| US20080275005A1 (en) | 1998-11-25 | 2008-11-06 | Murphy Michael P | Mitochondrially targeted antioxidants |
| US20070270381A1 (en) | 2000-05-25 | 2007-11-22 | Antipodean Pharmaceuticals, Inc. | Mitochondrially targeted antioxidants |
| US20020044913A1 (en) | 2000-02-11 | 2002-04-18 | Hamilton Nathan D. | Cosmetics to support skin metabolism |
| ITRM20010755A1 (it) | 2001-12-20 | 2003-06-20 | Simonelli Giuseppe | Uso del chinone q10 per il trattamento delle malattie oculari. |
| CA2397684A1 (en) | 2002-08-12 | 2004-02-12 | Michael P. Murphy | Mitochondrially targeted antioxidants |
| CA2583087C (en) | 2003-09-19 | 2012-07-10 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| CN1997403A (zh) | 2004-07-13 | 2007-07-11 | 奥里迪斯生物医学研究及开发有限责任公司 | 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途 |
| CA2578347A1 (en) * | 2004-08-30 | 2006-03-09 | Kaneka Corporation | Mitochondria activators |
| RU2318500C2 (ru) | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
| EA200900583A1 (ru) | 2006-10-20 | 2009-08-28 | Общество С Ограниченной Ответственностью "Митотехнология" | Композиция для регенерации, стимуляции роста и адаптации растений к различным стрессовым факторам |
| EA200900582A1 (ru) | 2006-10-20 | 2009-08-28 | Общество С Ограниченной Ответственностью "Митотехнология" | Фармацевтические композиции для профилактики и лечения глазных патологий |
| US9427444B2 (en) * | 2007-01-29 | 2016-08-30 | Mitotech Sa | Pharmaceutical and cosmetic compositions for accelerated healing of wounds and other surface damages |
| US9439916B2 (en) * | 2007-04-11 | 2016-09-13 | Mitotech Sa | Composition for decelerating the aging in the organism and for extending the life time thereof and the use of said composition |
| US8518915B2 (en) * | 2007-06-29 | 2013-08-27 | Mitotech Sa | Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases |
| WO2009158348A1 (en) * | 2008-06-25 | 2009-12-30 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| WO2010126909A1 (en) | 2009-04-28 | 2010-11-04 | Edison Pharmaceuticals, Inc. | Formulation of tocotrienol quinones for the treatment of ophthalmic diseases |
| JP5659388B2 (ja) * | 2009-06-10 | 2015-01-28 | マイトテック ソシエテ アノニム | 医学及び獣医眼科の使用のための医薬組成物 |
| CN102791670A (zh) * | 2009-11-13 | 2012-11-21 | 米拓科技有限责任公司 | 基于定向于线粒体的抗氧化剂的药物物质 |
| CN103764132B (zh) * | 2011-06-03 | 2017-04-12 | 米托特克公司 | 线粒体靶向的抗氧化剂的口服制剂及其制备和用途 |
-
2012
- 2012-06-04 CN CN201280027129.0A patent/CN103764132B/zh not_active Expired - Fee Related
- 2012-06-04 AU AU2012261854A patent/AU2012261854B2/en not_active Ceased
- 2012-06-04 BR BR112013030605A patent/BR112013030605A2/pt not_active Application Discontinuation
- 2012-06-04 CA CA2837437A patent/CA2837437C/en active Active
- 2012-06-04 ES ES12792111T patent/ES2704064T3/es active Active
- 2012-06-04 WO PCT/US2012/040711 patent/WO2012167236A1/en not_active Ceased
- 2012-06-04 EP EP12792111.2A patent/EP2714024B1/en active Active
- 2012-06-04 JP JP2014513785A patent/JP6448366B2/ja active Active
- 2012-06-04 EA EA201301321A patent/EA031399B1/ru not_active IP Right Cessation
- 2012-06-04 US US14/123,311 patent/US9192676B2/en active Active
-
2015
- 2015-10-20 US US14/887,406 patent/US9572890B2/en active Active
-
2017
- 2017-10-10 JP JP2017196849A patent/JP6461276B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515407A5 (OSRAM) | ||
| EP3043785B1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| ES2745471T3 (es) | Formulaciones orales de liberación inmediata para quinazolinonas sustituidas | |
| JP6462045B2 (ja) | スルフォラファンの単離及び精製 | |
| JP2009102342A5 (OSRAM) | ||
| JP2015530382A5 (OSRAM) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2016534063A5 (OSRAM) | ||
| JP2013511496A5 (OSRAM) | ||
| JP2013545730A5 (OSRAM) | ||
| JP2015515992A5 (OSRAM) | ||
| JP2020517727A5 (OSRAM) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| NZ703564A (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2016516772A (ja) | オキサシクロヘプタン及びオキサビシクロヘプテンの配合物 | |
| JP2013519653A5 (OSRAM) | ||
| JP2016516773A5 (OSRAM) | ||
| JP2018520198A5 (OSRAM) | ||
| US9713597B2 (en) | Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone | |
| RU2016138795A (ru) | Композиции на основе циклодекстрина и производного будесонида и способы их получения | |
| JP2011046708A5 (OSRAM) | ||
| CN104244936A (zh) | 镇痛剂 | |
| CN113101289A (zh) | 烟酰胺在制备治疗手足皮肤反应制剂中的应用 | |
| RU2018130097A (ru) | Лечение экземы кистей |